Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Advanced Bioresearch
mi
from
Miami, FL
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Advanced Bioresearch
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of Florida
mi
from
Pompano Beach, FL
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of Florida
mi
from
Pompano Beach, FL
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
The Kaufmann Clinic, Inc.
mi
from
Atlanta, GA
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
The Kaufmann Clinic, Inc.
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Indiana University, Eskanazi Hospital, Regenstrief Health Center
mi
from
Indianapolis, IN
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Indiana University, Eskanazi Hospital, Regenstrief Health Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Columbia Medical Practice
mi
from
Columbia, MD
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Columbia Medical Practice
mi
from
Columbia, MD
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Centennial Medical Associates
mi
from
Elkridge, MD
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Centennial Medical Associates
mi
from
Elkridge, MD
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Minnesota
mi
from
Rochester, MN
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Minnesota
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Nevada Family Care
mi
from
Henderson, NV
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Nevada Family Care
mi
from
Henderson, NV
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
United Medical Associates
mi
from
Binghamton, NY
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
United Medical Associates
mi
from
Binghamton, NY
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Regional Clinical Research, Inc.
mi
from
Endwell, NY
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Regional Clinical Research, Inc.
mi
from
Endwell, NY
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Sentral Clinical Research
mi
from
Cincinnati, OH
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Sentral Clinical Research
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Austin Regional Clinic
mi
from
Austin, TX
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Austin Regional Clinic
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Wasatch Clinical Research
mi
from
Salt Lake City, UT
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Wasatch Clinical Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Family Practice Center of Wooster, Inc./Clinical Trial Developers
mi
from
Wooster, OH
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Family Practice Center of Wooster, Inc./Clinical Trial Developers
mi
from
Wooster, OH
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Paragon Rx Clinical
mi
from
Garden Grove, CA
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Paragon Rx Clinical
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Next Phase Research Alliance
mi
from
Miami, FL
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Next Phase Research Alliance
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research, Inc.
mi
from
Meridian, ID
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research, Inc.
mi
from
Meridian, ID
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Pharmakon Inc.
mi
from
Evergreen Park, IL
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Pharmakon Inc.
mi
from
Evergreen Park, IL
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
MedPharmics, LLC.
mi
from
Metairie, LA
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
MedPharmics, LLC.
mi
from
Metairie, LA
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Comprehensive Internal Medicine, Inc.
mi
from
Wooster, OH
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Comprehensive Internal Medicine, Inc.
mi
from
Wooster, OH
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Harleysville Medical Associates
mi
from
Harleysville, PA
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Harleysville Medical Associates
mi
from
Harleysville, PA
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
PCP for Life (DM Research)
mi
from
Montgomery, TX
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
PCP for Life (DM Research)
mi
from
Montgomery, TX
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Facey Medical Foundation
mi
from
Mission Hills, CA
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Facey Medical Foundation
mi
from
Mission Hills, CA
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Health Awareness, Inc-Port St. Lucie
mi
from
Port Saint Lucie, FL
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Health Awareness, Inc-Port St. Lucie
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Precision Clinical Research
mi
from
Lauderdale Lakes, FL
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Precision Clinical Research
mi
from
Lauderdale Lakes, FL
Click here to add this to my saved trials
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
A Phase Ib/II Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Status: Enrolling
Updated:  12/31/1969
Cancer Treatment Center of America @ Western Regional Medical Center
mi
from
Goodyear, AZ
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
A Phase Ib/II Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Status: Enrolling
Updated: 12/31/1969
Cancer Treatment Center of America @ Western Regional Medical Center
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
A Randomized, Phase II Study of High-Risk Colorectal Cancer Patients (Stage IIIC) Treated With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
including Dallas, TX, Ocala, FL, Denver, CO, FL
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
A Randomized, Phase II Study of High-Risk Colorectal Cancer Patients (Stage IIIC) Treated With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
including Dallas, TX, Ocala, FL, Denver, CO, FL
Click here to add this to my saved trials
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated:  12/31/1969
Dana-Farber at Milford
mi
from
Milford, MA
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated: 12/31/1969
Dana-Farber at Milford
mi
from
Milford, MA
Click here to add this to my saved trials
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated:  12/31/1969
Dana-Farber at South Shore
mi
from
South Weymouth, MA
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated: 12/31/1969
Dana-Farber at South Shore
mi
from
South Weymouth, MA
Click here to add this to my saved trials
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated:  12/31/1969
Novant Health
mi
from
Winston-Salem, NC
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated: 12/31/1969
Novant Health
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University
mi
from
Richmond, VA
Improving Informed Consent for Palliative Chemotherapy
Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety, Tolerability, and Pharmacokinetics of Cobimetinib and GDC-0994 In Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Colorado
mi
from
Aurora, CO
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety, Tolerability, and Pharmacokinetics of Cobimetinib and GDC-0994 In Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety, Tolerability, and Pharmacokinetics of Cobimetinib and GDC-0994 In Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Yale Cancer Center
mi
from
New Haven, CT
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety, Tolerability, and Pharmacokinetics of Cobimetinib and GDC-0994 In Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety, Tolerability, and Pharmacokinetics of Cobimetinib and GDC-0994 In Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety, Tolerability, and Pharmacokinetics of Cobimetinib and GDC-0994 In Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety, Tolerability, and Pharmacokinetics of Cobimetinib and GDC-0994 In Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety, Tolerability, and Pharmacokinetics of Cobimetinib and GDC-0994 In Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety, Tolerability, and Pharmacokinetics of Cobimetinib and GDC-0994 In Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety, Tolerability, and Pharmacokinetics of Cobimetinib and GDC-0994 In Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Using Patients' Social Contact to Improve Out-Patient Endoscopy Among Blacks
Improving Attendance to Outpatient Endoscopy Among Blacks
Status: Enrolling
Updated:  12/31/1969
Howard University
mi
from
Washington,
Using Patients' Social Contact to Improve Out-Patient Endoscopy Among Blacks
Improving Attendance to Outpatient Endoscopy Among Blacks
Status: Enrolling
Updated: 12/31/1969
Howard University
mi
from
Washington,
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated:  12/31/1969
Hospital of the University of Pennsylvania Abramson Cancer Center
mi
from
Philadelphia, PA
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated: 12/31/1969
Hospital of the University of Pennsylvania Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated:  12/31/1969
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated: 12/31/1969
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated:  12/31/1969
University of Maryland, Greenbaum Cancer Center
mi
from
Baltimore, MD
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated: 12/31/1969
University of Maryland, Greenbaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, AZ
mi
from
Scottsdale, AZ
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, AZ
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated:  12/31/1969
Boca Raton Regional Hospital
mi
from
Boca Raton, FL
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated: 12/31/1969
Boca Raton Regional Hospital
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic - FL
mi
from
Jacksonville, FL
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic - FL
mi
from
Jacksonville, FL
Click here to add this to my saved trials